Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer
Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.
Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
2 Clarke Drive Cranbury, NJ 08512